Despite increasing use of continuous subcutaneous insulin infusion (CSII) pumps, the majority of people with T1D remain on multiple daily injections (MDI) with insulin,10 and MDI therapy is used for glycaemic control for significant numbers of people with T2D.11 This evidence concerns the gene INS and type 1 diabetes mellitus.